PURPOSE: To report the features of a case with late-onset fundus flavimaculatus (FFM) complicated by choroidal neovascularization (CNV) and treated with ranibizumab. METHODS: Retrospective interventional case report. PATIENT: A 51-year-old woman presented with right eye decreased vision. Fundus flavimaculatus with CNV was diagnosed by electroretinography and fluorescein angiography. RESULTS: Two intravitreal injections of ranibizumab were needed for the treatment. At the end of follow-up (9 months) no leakage was observed and visual acuity improved. CONCLUSION: Choroidal neovascularization is a rare complication of FFM. Ranibizumab, an anti-VEFG drug, stopped neovascularization and improved final visual acuity in this case, so it must be considered in the treatment of CNV in late onset FFM.
PURPOSE: To report the features of a case with late-onset fundus flavimaculatus (FFM) complicated by choroidal neovascularization (CNV) and treated with ranibizumab. METHODS: Retrospective interventional case report. PATIENT: A 51-year-old woman presented with right eye decreased vision. Fundus flavimaculatus with CNV was diagnosed by electroretinography and fluorescein angiography. RESULTS: Two intravitreal injections of ranibizumab were needed for the treatment. At the end of follow-up (9 months) no leakage was observed and visual acuity improved. CONCLUSION: Choroidal neovascularization is a rare complication of FFM. Ranibizumab, an anti-VEFG drug, stopped neovascularization and improved final visual acuity in this case, so it must be considered in the treatment of CNV in late onset FFM.